X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs SANOFI INDIA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD SANOFI INDIA ALEMBIC LTD/
SANOFI INDIA
 
P/E (TTM) x 61.1 39.5 154.7% View Chart
P/BV x 2.6 8.5 29.9% View Chart
Dividend Yield % 0.4 1.1 37.8%  

Financials

 ALEMBIC LTD   SANOFI INDIA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
SANOFI INDIA
Dec-16
ALEMBIC LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs724,560 1.6%   
Low Rs344,400 0.8%   
Sales per share (Unadj.) Rs4.71,028.5 0.5%  
Earnings per share (Unadj.) Rs6.1129.0 4.7%  
Cash flow per share (Unadj.) Rs6.2186.0 3.4%  
Dividends per share (Unadj.) Rs0.2068.00 0.3%  
Dividend yield (eoy) %0.41.5 24.9%  
Book value per share (Unadj.) Rs40.7753.6 5.4%  
Shares outstanding (eoy) m267.0323.03 1,159.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.4 258.6%   
Avg P/E ratio x8.734.7 25.0%  
P/CF ratio (eoy) x8.524.1 35.2%  
Price / Book Value ratio x1.35.9 21.9%  
Dividend payout %3.352.7 6.2%   
Avg Mkt Cap Rs m14,139103,174 13.7%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m2073,592 5.8%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m1,25523,686 5.3%  
Other income Rs m370708 52.3%   
Total revenues Rs m1,62524,394 6.7%   
Gross profit Rs m1115,281 2.1%  
Depreciation Rs m381,313 2.9%   
Interest Rs m215 11.3%   
Profit before tax Rs m4424,661 9.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m241,691 1.4%   
Profit after tax Rs m1,6302,970 54.9%  
Gross profit margin %8.922.3 39.7%  
Effective tax rate %5.436.3 14.9%   
Net profit margin %129.812.5 1,035.5%  
BALANCE SHEET DATA
Current assets Rs m1,86715,673 11.9%   
Current liabilities Rs m5916,678 8.9%   
Net working cap to sales %101.638.0 267.7%  
Current ratio x3.22.3 134.6%  
Inventory Days Days9476 124.0%  
Debtors Days Days7422 329.6%  
Net fixed assets Rs m1,7918,098 22.1%   
Share capital Rs m534230 231.9%   
"Free" reserves Rs m10,32417,088 60.4%   
Net worth Rs m10,85817,356 62.6%   
Long term debt Rs m410-   
Total assets Rs m11,59125,400 45.6%  
Interest coverage x260.9311.7 83.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.9 11.6%   
Return on assets %14.111.8 119.8%  
Return on equity %15.017.1 87.7%  
Return on capital %15.226.9 56.4%  
Exports to sales %1.524.5 6.3%   
Imports to sales %21.028.0 75.0%   
Exports (fob) Rs m195,801 0.3%   
Imports (cif) Rs m2636,627 4.0%   
Fx inflow Rs m197,145 0.3%   
Fx outflow Rs m2646,846 3.9%   
Net fx Rs m-244299 -81.7%   
CASH FLOW
From Operations Rs m2363,226 7.3%  
From Investments Rs m-224-1,555 14.4%  
From Financial Activity Rs m-27-1,818 1.5%  
Net Cashflow Rs m-15-147 10.1%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.2 14.4 1.4%  
FIIs % 9.7 14.6 66.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 15,184 360.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare ALEMBIC LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - CADILA HEALTHCARE COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS